Welcome!

News Feed Item

Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)

DUBLIN, March 13, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/jdzmv4/nasal_drug) have announced the addition of the "Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)" conference to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The Nasal Drug Delivery Conference will take place on the 3rd & 4th April 2014 at the Rembrandt Hotel, London

THREE REASONS TO ATTEND THIS EVENT

- Gain an update on the very latest scientific developments and technology advances in this field.

- Hear from an unrivaled panel of expert speakers.

- An excellent networking opportunity to build business relationships.

WHO SHOULD ATTEND

Managing Directors, Medical Directors, Head of Regulatory Affairs and Quality Assurance, Senior Executives in Research and Development, Registration, Marketing and all departments that may be involved in Nasal Drug Delivery, or who wish to understand the potential of this alternative therapeutic route. Those already involved in Nasal Drug Delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in Nasal Drug Delivery or are just considering the potential, this conference is an excellent route to understanding all aspects from the basic physiology through to launching a successful product. 

CHAIRPERSON: Dr Rene Bommer

KEYNOTE SPEAKER: Prof. Michael S Benninger

DATES:

3 & 4 April 2014

TIMES:

3 April 2014: Start 09.30 - Finish 17.30
Drinks Reception: Start 17.30 - Finish 18.30
4 April 2014: Start 09.15 - Finish 16.30

REGISTRATION & COFFEE

3 April 2014 09.00

VENUE & ACCOMMODATION

The Rembrandt Hotel, 11 Thurloe Place, London SW7 2RS

DIRECTIONS:

Opposite V&A Museum. Nearest underground station: South Kensington.

NOTE: Events may be cancelled due to commercial or organisational reasons. In this case Research and Markets will refund all registration fees which have already been paid. Research and Markets will not refund any charges arising from the participant having to cancel or re-book transportation or accommodation which he or she has arranged 

Key Topics Covered: 

DAY ONE - 3 April 2014

09.30 u Chairman's Welcome and Introduction
Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 1: Advances in Drug Therapies: State of the Art

09.45 u Nasal Drugs to Treat Nasal Disorders; A Comprehensive Review

- Anatomy and physiology
- Nasal disorders
- Treatment options and future prospects to treat allergic and non-allergic Rhinitis
- Rhinosinusitis and Polyps

Professor Michael S. Benninger, Chairman, The Head and Neck Institute, Professor of Surgery, Lerner College of Medicine, The Cleveland Clinic, USA 

10.45 - Discussion 

11.00 - Coffee

Session 2: Progress in Local and Systemic Nasal Drug Delivery

11.30 - Particulate Systems for Nasal (Vaccine) Delivery

- Literature review on particulate systems for nasal delivery
- Nanoparticulate systems for direct uptake
- Particle requirements for nasal deposition
- Modification of particle surface/particle engineering
- Formulation design
- Implications in nasal vaccine development

Dr Regina Scherliess, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany

12.10 - Antiviral Polymers - A Novel Concept of Intranasal Therapy Against Respiratory Viruses

- Marinomed has developed a technology for creating a protective physical barrier in the nasal cavity with antiviral polymers for the prevention and therapy of common cold and influenza

- Independent clinical trials in adults and children demonstrated that the intranasal administration of Iota-Carrageenan significantly reduced the time to disease clearance of patients with common cold and decreased the virus load in nasal lavages

- The existing product portfolio will be expanded and the new developments focus on combination products for the treatment of influenza and the prevention of virally-induced exacerbations in allergic patients 

Dr Angelika Bodenteich, Head of Development, Marinomed Biotechnologie, GmbH, Germany

12.50 - Discussion

13.00 - Lunch

14.00 - Nasal Drug Delivery - The Technology Whose Potential Has Not Yet Been Valorised

- Current technologies for nasal drug delivery
- Nasal application for unmet medical needs
- Factors affecting bioavailability and response after nasal application
- Symbiosis of formulation and device
- Identification of potential obstacles in product development

Dr Claudia Mattern, Adjunct Professor Nova Southeastern University, US-FL, Chief Scientific Officer, M & P Pharma AG, Switzerland 

Session 3: Nasal Devices, Device Testing and New Technologies

14.40 - Review of Nasal Drug Delivery Devices

- Business aspects
- Device technologies and nasal delivery systems
- Regulatory aspects
- Nasl spray characterisation 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

15.20 - Discussion 

15.30 - Tea

16.00 - New Trends in Nasal Delivery with Dry Powder Formulations

- Dry powder formulations represent attractive alternatives to liquid formulations

- Systemic delivery via the nasal cavity, including pain treatments and also intra-nasal vaccination, are being investigated and developed with dry powder formulation because it offers a number of benefits like thermal and microbiologic stability and the variability of the physico-chemical properties

- Regulatory Aptar pharma offers a line of disposable primeless devices designed specifically for liquid and for dry powder formulations

- Opportunities and case studies using our Unit Dose Powder, Single Dose Device technology platform

Holger Kehrer, Business Support Manager, Aptar pharma, France 

16.40 - Update on Advancia: Innovative Design Solution to Respond to New Challenges in Nasal Delivery

- Recent trends in nasal spray delivery
- Compliance, efficiency, convenience and ease of use of nasal delivery devices
- Regulatory requirement changes for nasal delivery requiring next generation devices

Pascale Farjas, Global Category Manager, Rexam Healthcare, France 

17.20 - Discussion 

17.30 - Close of Day One

17.30 - 18.30 Drinks Reception for Delegates and Speakers

DAY TWO - 4 April 2014

09.15 - Chairman's Review of Day One 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 4: Nasal Devices, Device Testing and New Technologies (continued)

09.30 - Current Nasal Powder Technologies: The Challenge of Powder Dosing

- Dosing requirements (dosing range, target to be filled, powder properties)
- Overview dosing systems (design, functionality)
- Examples of filling equipment (developmental equipment)
- Systems for fill weight verification (IPC, PAT,..)

Marco Laackmann, Division Leader, Inhalation, Harro Höfliger, Germany 

10.10 - Addressing Technical Barriers in Nasal Dry Powder Delivery 

- Patient / user needs - clinical trials, comfort, understanding
- Device requirements - materials, regulatory, risks
- Formulation requirements - dosage, residence time, stability
- Product performance - deposition, particle size distribution, plume geometry, shelf life
- Commercialisation - competition, cost, IP, market need, regulatory acceptance, USP

Ian Harrison, Chief Scientific Officer, Alchemy Pharmatech, UK 

10.50 - Discussion

11.00 - Coffee

11.30 - How Technology Can be Used to Enhance our Understanding of User Behaviour and Influence the Way we Conduct User Research

- Social Intelligence for greater product understanding
- Gaining access to the right study participants
- Field research from your desk
- Quantifying human performance
- Seeing through our users eyes
- Understanding emotional responses and states of mind

Miranda Newberry, Human Factors Consultant, PA Consulting, UK

12.10 - A Platform Approach to Developing Patient Oriented Drug Delivery Systems and Products

- This approach to the development of drug delivery technology solutions is unconventional, risky and offers tremendous potential for developing drug/device combination products that deliver unparalleled value to both the patient and the manufacturer

- This well-executed platform based approach seeks to reduce the complexity of developing new combination products without sacrificing innovation

- Progress of Mystic's drug delivery platform solutions, its capabilities, applications and the benefits for patients and Pharma/biotech manufacturers
Timothy Sullivan, President & CEO, Mystic Pharmaceuticals Inc., USA (invited)

12.50 - Discussion

13.00 - Lunch

Session 5: Regulatory Requirements

14.00 - EU Regulatory Requirements 

- Differences between pulmonary and nasal requirements
- Bio-equivalence Representative from a Regulatory Agency, (invited)

14.40 - Discussion

Session 6: Business and Intellectual Property (IP) in Nasal Systemic Drug Delivery

14.50 - Choosing the Best Way to Finance Your Company 

- First: get the business model right
- Starting out - is there easy money?
- Angels vs Dragons
- Dilutive vs non-dilutive financing
- Financing through partnering
- Planning an exit - IPO vs Trade Sale

Finton Walton, CEO, Pharma Ventures, UK

15.30 - R&D Collaborations for Drug Delivery: Legal and Contractual Issues

- The different priorities of universities, start-ups and major companies
- Benefits of term sheets / letters of intent and how to use them
- Defining the scope of the collaboration: work, field, etc.
- IP ownership and licences
- Other legal issues

Mark Anderson, Solicitor, Anderson Law LLP, UK

16.10 u Discussion

16.20 u Chairman's Concluding Remarks

16.30 u Close of Conference and Tea 

For more information visit http://www.researchandmarkets.com/research/jdzmv4/nasal_drug

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...